Trial · NCT01041638
Results by group92
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 92
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Abdominal pain (10300), course 1 | 17.3077 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Abdominal pain (10300), course 2 | 5.0000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Abdominal pain (10300), course 3 | 6.1224 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Abdominal pain (10300), course 4 | 4.4444 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Abdominal pain (10300), course 5 | 5.6818 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Abdominal pain (10300), course 6 | 0.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Allergic reaction (12000), Course 1 | 1.92308 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Allergic reaction (12000), Course 2 | 5.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Allergic reaction (12000), Course 3 | 3.06122 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Allergic reaction (12000), Course 4 | 2.22222 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Allergic reaction (12000), Course 5 | 1.13636 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Allergic reaction (12000), Course 6 | 0.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anal pain (12800), Course 1 | 0.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anal pain (12800), Course 2 | 1.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anal pain (12800), Course 3 | 0.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anal pain (12800), Course 4 | 0.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anal pain (12800), Course 5 | 0.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anal pain (12800), Course 6 | 0.00000 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anaphylaxis (13100), Course 1 | 0.96154 | percentage of participants | |
| Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). | Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin | Anaphylaxis (13100), Course 2 | 4.00000 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01041638/results